Portfolio

Zimmer BioTech

As early as 2012, Zimmer contributed to the development of a drug based on the compound 5-Aminolevulinic acid for use in the treatment of actinic keratoses. The spin-off Zimmer BioTech has been active since October 2016 and is funded by Bonn-based High-Tech Gründerfonds, Germany’s largest seed stage investor. Alevin deep, the first drug to be developed by Zimmer BioTech, is expected to receive approval by 2020.

Pressemeldungen

Spin-off of Neu-Ulm-based medical device producer develops drug to treat skin cancer – Zimmer BioTech expands development team

In Dr. Reinhold Gahlmann and Stuart Marcus, Neu-Ulm-based Zimmer BioTech has now hired two experts in the field of pharmaceutical development. As Head of Clinical Development, Dr. Gahlmann will be responsible for establishing and implementing the clinical development programme…
Read

Neu-Ulm-based medical device producer and High-Tech Gründerfonds found spin-off Zimmer BioTech: New therapy to combat skin cancer

In the field of dermatology, Zimmer MedizinSysteme GmbH, a company based in Neu-Ulm (southern Germany), has long been the global market leader for cryotherapy products. In founding the spin-off Zimmer BioTech, the company is now taking another step forward and utilising its wealth of experience to treat skin cancer.…
Read

Info & Contact

Phone:
+49 7 3197610
Web:
zimmer.de

Address

Zimmer MedizinSysteme GmbH
Junkersstraße 9
89231 Neu-Ulm

In portfolio

13. Jun 2017